Skip to main content
OpenTrials
Completed

NCT Number: NCT00705718

Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System

To demonstrate safety and effectiveness of the Endurant Stent Graft in the treatment of Abdominal Aortic or Aorto-Uni-Iliac Aneurysms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Abdominal Aortic Aneurysms Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal Aortic Diseases Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama Hospitals, Birmingham, Alabama, United States

Loading trial locations.

About this study

Prospective, two-arm, non-randomized, multicenter clinical study enrolling subjects treated with the bifurcated stent graft in one arm and subjects treated with the AUI in a second arm.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 18 years old.
  • Subject (or Subject's legal representative) understands and voluntarily has signed and dated an Informed Consent document approved by the Sponsor and by the Institutional Review Board.
  • Subject is able and willing to comply with the protocol and undergo follow-up requirements.
  • Subject is a suitable candidate for elective surgical repair of AAA by as evaluated by American Society of Anesthesiologists (ASA) Physical Status Classification System I, II, III, or IV
  • Subject has an abdominal aortic or aortoiliac aneurysm characteristics that meet protocol parameter
  • Subject meets all the protocol anatomical criteria* as demonstrated on contrast-enhanced CT or MRA
  • Subject has vascular dimensions in the range of sizes available for the Endurant Stent Graft
  • Subject has documented imaging evidence of at least 1 patent iliac and 1 femoral artery, or can tolerate a vascular conduit that allows introduction of the device.
  • Subject's native vessel anatomy is more suited for the introduction and/ or deployment of an Endurant Uni-Iliac Stent Graft System.

Exclusion criteria

  • Subject has a life expectancy < 1 year
  • Subject is participating in another investigational drug or device study
  • Subject requires emergent aneurysm treatment
  • Subject is a female of childbearing potential in whom pregnancy cannot be excluded.
  • Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.
  • Subject is morbidly obese (body mass index ≥ 40 kg/m2) or has other documented clinical conditions that severely inhibit radiographic visualization of the aorta.

Treatment and study plan

Endurant Stent Graft System

Device

Abdominal Aortic Aneurysm Repair

Other names: Endovascular treatment of Abdominal Aortic Aneurysm

Primary outcomes

  1. Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure)

    Time frame: 30 days (Safety)

    The primary safety endpoint is composite defined as the proportion of subjects free from major adverse events (MAE) within 1 month (day 0 - Day 30)of implant is non-inferior to the proportion of subjects free from MAEs in the Talent Control Group. The endpoint is defined as the proportion of subjects free from occurence of a MAE within 1 month of the implantation of the Endurant Stent Graft. The major adverse events composite endpoint which will be evaluated at 1 month post implant includes the occurrence of any of the following events.

    • All-Cause Mortality
    • Bowel Ischemia
    • Myocardial Infarction
    • Paraplegia
    • Procedural Blood Loss > or equal to 1000 cc
    • Renal Failure
    • Respiratory Failure
    • Stroke

  2. Major Adverse Events Within 30 Days of Index Procedure

    Time frame: 30 days

    The primary safety endpoint is composite defined as the proportion of subjects free from major adverse events (MAE) within 1 month (day 0 - Day 30)of implant is non-inferior to the proportion of subjects free from MAEs in the Talent Control Group. The endpoint is defined as the proportion of subjects free from occurence of a MAE within 1 month of the implantation of the Endurant Stent Graft. The major adverse events composite endpoint which will be evaluated at 1 month post implant includes the occurrence of any of the following events.

    • All-Cause Mortality
    • Bowel Ischemia
    • Myocardial Infarction
    • Paraplegia
    • Procedural Blood Loss > or equal to 1000 cc
    • Renal Failure
    • Respiratory Failure
    • Stroke

  3. Primary Effectiveness Endpoint (Technical Success)

    Time frame: Intra-operatively

    Technical success defined as successful delivery and deployment of the stent graft in the planned location and with no unintentional coverage of both the internal iliac arteries or any visceral aortic branches and with removal of the system. Technical success was assessed intra-operatively.

  4. Primary Effectiveness Endpoint (Treatment Success)

    Time frame: 12 months

    Treatment success is defined as Technical success and the following:

    • Freedom from AAA diameter increased, defined as >5 mm increase in maximum diameter as measured on CT scan (or MRA/MRI) at 12 months as compared to 1 month
    • Freedom from Types I and III endoleaks at 12 months including those requiring intervention through 12 months
    • Freedom from aneurysm rupture through 12 months
    • Freedom from conversion to surgery through 12 months
    • Freedom from stent graft migrations resulting in a serious adverse event or requiring secondary intervention through 12 months
    • Freedom from stent graft occlusion at 12 months

Secondary outcomes

  1. Secondary Endpoints - Safety Evaluation

    Time frame: 12 months

    The following secondary endpoints were included in the Pivotal trial to evaluate the safety profile of the Endurant Stent Graft System.

    • Aneurysm-Related Mortality through 12 months
    • All-Cause Mortality with 30 days
    • All-Cause Mortality within 12 months
    • Major Adverse Events through 12 months
    • Adverse Events through 12 months
    • Unanticipated Adverse Device Events
    • Serious Adverse Events (SAEs) As reported at the time of the data cut off.
    • Device Related Adverse Events
    • Procedure Related Adverse Events
    • Adverse Events (excluding SAEs)

  2. Secondary Endpoint - Effectiveness Evaluation

    Time frame: 12 months

    The following secondary endpoints were included in the pivotal trial to evaluate the effectiveness profile of the Endurant Stent Graft System.

    • Stent Graft migration through 12 months
    • Stent Graft Patency through 12 months
    • All stent Graft Endoleaks at 1-month, 6-months, and 12-month
    • Secondary Procedures to correct Type I and type III Endoleaks through 12 months
    • Secondary Endovascular Procedures through 12 months
    • Technical Observations through 12 months

Sponsors and collaborators

Lead sponsor

Medtronic Cardiovascular

Industry

Registry information

Official study title

Endurant Stent Graft System US Clinical Study

Important dates

Study start
2008
Primary completion
2012
Study completion
2016
First posted
Jun 26, 2008
Registry last updated
Nov 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.